Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03808662 · ClinicalTrials.gov registry record · Phase 2
Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung
A Phase 2 study of Non-Small Cell Lung Cancer and Triple Negative Breast Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 107
- Enrollment target
- 10
- Study locations
NCT03808662 is a Phase 2 study of Non-Small Cell Lung Cancer and Triple Negative Breast Cancer that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 107 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (84% lower). The trial reports 10 study locations across 4 states.
The verdict
NCT03808662, a Phase 2 study of Non-Small Cell Lung Cancer and Triple Negative Breast Cancer, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 107 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this study is determine if receiving stereotactic body radiation(SBRT) when participants' metastatic tumors have just begun to grow increase the length of time before disease gets worse
Conditions Studied
Interventions
- DRUG Standard of care
- RADIATION Sterotactic Body Radiotherapy/SBRT
Study Locations (10)
New York
- Memorial Sloan Kettering Commack - Commack
- Memorial Sloan Kettering Westchester - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Rockville Centre - Rockville Centre
- Memorial Sloan Kettering Nassau - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge - Basking Ridge
- Memorial Sloan Kettering Monmouth - Middletown
- Memorial Sloan Kettering Bergen - Montvale
Washington
- Fred Hutchinson Cancer Research Center (Data Analysis Only) - Seattle
Ontario
- Princess Margaret Hospital/Ontario Cancer Institute (Data Analysis Only) - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2019-01-16 |
| Est. Completion | 2027-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03808662
The ClinicalTrials.gov registry entry for NCT03808662 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 107 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (84% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Standard of care is the first listed.
NCT03808662 reports 10 study locations spanning 4 distinct geographic areas - top geographies include New York, New Jersey, Washington.
Frequently Asked Questions
What is clinical trial NCT03808662 about?
NCT03808662 is a clinical study titled "Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung". The purpose of this study is determine if receiving stereotactic body radiation(SBRT) when participants' metastatic tumors have just begun to grow increase the length of time before disease gets worse
What is the current status of trial NCT03808662?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 107 participants. The study started on 2019-01-16. Estimated completion is 2027-01.
What conditions does trial NCT03808662 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Triple Negative Breast Cancer, NSCLC, TNBC - Triple-Negative Breast Cancer, Non Small Cell Lung Cancer Metastatic.
What interventions are being tested in trial NCT03808662?
The interventions under investigation include: Standard of care (DRUG), Sterotactic Body Radiotherapy/SBRT (RADIATION).
Who is sponsoring clinical trial NCT03808662?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03808662 being conducted?
This trial has 10 study locations across New Jersey, New York, Washington, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.